Acerus Pharmaceuticals Corporation announced earnings results for the third quarter ended September 30, 2020. For the third quarter, the company announced operating loss was USD 6.644 million compared to USD 3.849 million a year ago. Net loss was USD 7.048 million compared to USD 4.612 million a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.02 a year ago. For the nine months, operating loss was USD 15.949 million compared to USD 10.542 million a year ago. Net loss was USD 17.321 million compared to USD 12.246 million a year ago. Basic loss per share from continuing operations was USD 0.02 compared to USD 0.05 a year ago.